SCHEMBL1025987

SCHEMBL1025987

OB(O)C=CCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025985 1.00
SCHEMBL3575500 0.71
SCHEMBL3575503 0.71
SCHEMBL6977352 0.69
SCHEMBL944868 0.67
SCHEMBL1809769 0.67
SCHEMBL27873199 0.67
SCHEMBL14061003 0.67
SCHEMBL4194764 0.67
SCHEMBL151293 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688906-B2 Boronated biopolymer crosslinking agents and methods relating thereto HALLIBURTON ENERGY SERVICS, INC. (US) 2017-06-27 US claimed
US-9340575-B2 Agonists and antagonists of the urotensinergic system INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2016-05-17 US claimed
US-20150075789-A1 Boronated Biopolymer Crosslinking Agents and Methods Relating Thereto HALLIBURTON ENERGY SERVICES, INC. (US) 2015-03-19 US claimed
WO-2015002669-A1 BORONATED BIOPOLYMER CROSSLINKING AGENTS AND METHODS RELATING THERETO HALLIBURTON ENERGY SERVICES, INC. (US) 2015-01-08 WO claimed
EP-2729184-A1 NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM Institut National de la Recherche Scientifique (CA) 2014-05-14 EP claimed
US-20140113872-A1 NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2014-04-24 US claimed
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
WO-2012149644-A1 NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2012-11-08 WO claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-12428419-B2 Therapeutic compounds GENENTECH, INC. (US) 2025-09-30 US disclosed
US-20240383897-A1 THERAPEUTIC COMPOUNDS GENENTECH, INC. (US) 2024-11-21 US disclosed
EP-4384517-A1 PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM Genentech, Inc. (US) 2024-06-19 EP disclosed
US-11993599-B2 Therapeutic compounds GENENTECH, INC. (US) 2024-05-28 US disclosed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO disclosed
US-20070082880-A1 Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors WYETH 2007-04-12 US disclosed
WO-2007038519-A1 THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS WYETH (US) 2007-04-05 WO disclosed
US-20060224011-A1 Catalyst composition and process for producing cross-coupled compound using same TOSOH CORPORATION 2006-10-05 US disclosed
EP-1707263-A1 Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same Tosoh Corporation (JP) 2006-10-04 EP disclosed